Novaccess Global Inc XSNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if XSNX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.01–0.22
- Bid/Ask
- $0.01 / $0.01
- Market Cap
- $141,135.22
- Volume/Avg
- 3.5 Mil / 530,970
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Novaccess Global Inc is a biopharmaceutical company that is developing novel immunotherapies to treat brain tumor patients in the United States. The company's team of experts is working to strengthen the capability of the human body’s defense against cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- —
- Website
- https://www.novaccessglobal.com
Valuation
|
Metric
|
XSNX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
XSNX
Financial Strength
|
Metric
|
XSNX
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 0.00 |
Interest Coverage | 0.21 |
Quick Ratio
XSNX
Profitability
|
Metric
|
XSNX
|
|---|---|
Return on Assets (Normalized) | −3,504.98% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
XSNX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wtjkltxpd | Mgjlj | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qffsgxlw | Yjcrkz | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sqmwpsyc | Tzbdtx | $97.8 Bil | |
MRNA
| Moderna Inc | Nzqzgvxbw | Hmbx | $41.3 Bil | |
ARGX
| argenx SE ADR | Rtcslrhpq | Ptlhn | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Vqjmtdzr | Mzf | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bhgwtdgsx | Kjdblvq | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fbzhvkqyk | Jljgfs | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ffdbmjdtps | Wpqyqw | $12.5 Bil | |
INCY
| Incyte Corp | Ykfvzzdbn | Nvrsyq | $11.6 Bil |